Terms: = Breast cancer AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254
108 results:
1. Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative breast cancer: MRPS27 as a Key Mediator of the Stemness-inhibitory Effect of Lovastatin.
Zheng C; Yao H; Lu L; Li H; Zhou L; He X; Xu X; Xia H; Ding S; Yang Y; Wang X; Wu M; Xue L; Chen S; Peng X; Cheng Z; Wang Y; He G; Fu S; Keller ET; Liu S; Jiang YZ; Deng X
Int J Biol Sci; 2024; 20(6):2130-2148. PubMed ID: 38617541
[TBL] [Abstract] [Full Text] [Related]
2. Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.
Franzoi MA; Aupomerol M; Havas J; Soldato D; Lambertini M; Massarotti C; Hang H; Pistilli B; Fasse L; Tredan O; Gillanders E; Joly F; Cottu P; Mouret-Reynier MA; Tarpin C; Arnaud A; Everhard S; Martin AL; Di Meglio A; Vaz-Luis I
ESMO Open; 2024 Feb; 9(2):102236. PubMed ID: 38350335
[TBL] [Abstract] [Full Text] [Related]
3. PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex.
Jin J; Bai H; Yan H; Deng T; Li T; Xiao R; Fan L; Bai X; Ning H; Liu Z; Zhang K; Wu X; Liang K; Ma P; Gao X; Hu D
Nat Commun; 2023 Nov; 14(1):7274. PubMed ID: 37949879
[TBL] [Abstract] [Full Text] [Related]
4. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ breast cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.
Wildiers H; Armstrong A; Cuypere E; Dalenc F; Dirix L; Chan S; Marme F; Schröder CP; Huober J; Duhoux FP; Vuylsteke P; Jager A; Brain E; Kuemmel S; Pápai Z; Menke-van der Houven van Oordt CW; Perjesi L; Mueller C; Brignone C; Triebel F
Clin Cancer Res; 2024 Feb; 30(3):532-541. PubMed ID: 37939105
[TBL] [Abstract] [Full Text] [Related]
5. LC/MS-based untargeted lipidomics reveals lipid signatures of nonpuerperal mastitis.
Chen X; Shao S; Wu X; Feng J; Qu W; Gao Q; Sun J; Wan H
Lipids Health Dis; 2023 Aug; 22(1):122. PubMed ID: 37553678
[TBL] [Abstract] [Full Text] [Related]
6. Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive breast cancer.
Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zimmermann F; Montagna G; Fitzal F; Gnant M; Ruhstaller T; Muenst S; Mueller A; Lelièvre L; Heil J; Knauer M; Egle D; Sávolt Á; Heidinger M; Kurzeder C; ; Zwahlen DR; Gruber G; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Smanykó V; Vrieling C; Satler R; Hagen D; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Loibl S; Winkler J; Lam GT; Fehr MK; Kohlik M; Clerc K; Ostapenko V; Maggi N; Schulz A; Andreozzi M; Goldschmidt M; Saccilotto R; Markellou P
JAMA Surg; 2023 Oct; 158(10):1013-1021. PubMed ID: 37466971
[TBL] [Abstract] [Full Text] [Related]
7. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
[TBL] [Abstract] [Full Text] [Related]
8. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Tausch C; Däster K; Hayoz S; Matrai Z; Fitzal F; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Andreozzi M; Goldschmidt M; Schulz A; Maggi N; Saccilotto R; Heidinger M; Mueller A; Tampaki EC; Bjelic-Radisic V; Sávolt Á; Smanykó V; Hagen D; Müller DJ; Gnant M; Loibl S; Markellou P; Bekes I; Egle D; Ruhstaller T; Muenst S; Kuemmel S; Vrieling C; Satler R; Becciolini C; Bucher S; Kurzeder C; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Montagna G; Reitsamer R; Winkler J; Lam GT; Fehr MK; Naydina T; Kohlik M; Clerc K; Ostapenko V; Lelièvre L; Heil J; Knauer M; Weber WP
Breast Cancer Res Treat; 2023 Sep; 201(2):215-225. PubMed ID: 37355526
[TBL] [Abstract] [Full Text] [Related]
9. Mutant npm1 maintains RASGRP3 protein stability via interaction with MID1 to promote acute myeloid leukemia cell proliferation and autophagy.
Wang Y; Pan C; Zhang X; Zhao A; Dong Y
J Leukoc Biol; 2023 May; 113(5):504-517. PubMed ID: 36826998
[TBL] [Abstract] [Full Text] [Related]
10. Biomedical Indicators of Patients with Non-Puerperal Mastitis: A Retrospective Study.
Shi L; Wu J; Hu Y; Zhang X; Li Z; Xi PW; Wei JF; Ding Q
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432503
[TBL] [Abstract] [Full Text] [Related]
11. Life after Cleavage: The Story of a β-Retroviral (MMTV) Signal Peptide-From Murine Lymphoma to Human breast cancer.
Hochman J; Braitbard O
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366533
[TBL] [Abstract] [Full Text] [Related]
12. Clinical outcomes associated with npm1 mutations in patients with relapsed or refractory AML.
Issa GC; Bidikian A; Venugopal S; Konopleva M; DiNardo CD; Kadia TM; Borthakur G; Jabbour E; Pemmaraju N; Yilmaz M; Short NJ; Maiti A; Sasaki K; Masarova L; Pierce S; Takahashi K; Tang G; Loghavi S; Patel K; Andreeff M; Bhalla K; Garcia-Manero G; Ravandi F; Kantarjian H; Daver N
Blood Adv; 2023 Mar; 7(6):933-942. PubMed ID: 36322818
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.
Nilsson C; Linde F; Hulegårdh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jädersten M; Björkvall CK; Möllgård L; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Haematologica; 2023 Apr; 108(4):1015-1025. PubMed ID: 36005563
[TBL] [Abstract] [Full Text] [Related]
14. Myeloid Sarcoma of the breast as Blast Phase of JAK2-Mutated (Val617Phe Exon 14p) Essential Thrombocythemia: A Case Report and a Systematic Literature Review.
Pace M; Guadagno E; Russo D; Gencarelli A; Carlea A; Di Spiezio A; Bertuzzi C; Mascolo M; Grimaldi F; Insabato L
Pathobiology; 2023; 90(2):123-130. PubMed ID: 35850113
[TBL] [Abstract] [Full Text] [Related]
15. Ultrasonic multimodality imaging features and the classification value of nonpuerperal mastitis.
Li C; Yao M; Li X; Shao S; Chen J; Li G; Jia C; Wu R
J Clin Ultrasound; 2022 Jun; 50(5):675-684. PubMed ID: 35475482
[TBL] [Abstract] [Full Text] [Related]
16. Interactions between the breast tissue microbiota and host gene regulation in nonpuerperal mastitis.
Zhu J; Wu J; Liang Z; Mo C; Qi T; Liang S; Lian T; Qiu R; Yu X; Tang X; Wu B
Microbes Infect; 2022; 24(3):104904. PubMed ID: 35331909
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
Wong SM; Ajjamada L; Weiss AC; Prakash I; Skamene S; Boileau JF; Pollak MN; Basik M
Cancer; 2022 Apr; 128(7):1365-1372. PubMed ID: 34919263
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with breast cancer.
Al-Shamsi HO; Abu-Gheida I; Abdulsamad AS; AlAwadhi A; Alrawi S; Musallam KM; Arun B; Ibrahim NK
Oncologist; 2021 Nov; 26(11):e2086-e2089. PubMed ID: 34327780
[TBL] [Abstract] [Full Text] [Related]
19. Next generation sequencing in therapy-related myeloid neoplasms compared to
Claerhout H; Vranckx H; Lierman E; Michaux L; Boeckx N
Acta Clin Belg; 2022 Jun; 77(3):658-663. PubMed ID: 34197279
[TBL] [Abstract] [Full Text] [Related]
20. PSMD9 ribosomal protein network maintains nucleolar architecture and WT p53 levels.
Ud Din Farooqee SB; Christie J; Venkatraman P
Biochem Biophys Res Commun; 2021 Jul; 563():105-112. PubMed ID: 34077860
[TBL] [Abstract] [Full Text] [Related]
[Next]
